	US 12,274,715 B2
	Method for maximizing coronavirus killing activity of high-density lipoproteins, and pharmaceutical composition for preventing or treating COVID-19
Kyung-Hyun Cho, Daegu (KR)
Assigned to Raydel Korea Co., Ltd., Seoul (KR)
Appl. No. 18/253,999
Filed by RAYDEL KOREA CO., LTD., Seoul (KR)
PCT Filed Dec. 22, 2021, PCT No. PCT/KR2021/019587 § 371(c)(1), (2) Date May 23, 2023, PCT Pub. No. WO2022/154297, PCT Pub. Date Jul. 21, 2022.
Claims priority of application No. 10-2021-0004421 (KR), filed on Jan. 13, 2021.
Prior Publication US 2023/0390333 A1, Dec. 7, 2023
Int. Cl. A61K 35/16 (2015.01); A61P 31/14 (2006.01); C12Q 1/44 (2006.01); G01N 33/92 (2006.01)

CPC A61K 35/16 (2013.01) [A61P 31/14 (2018.01); C12Q 1/44 (2013.01); G01N 33/92 (2013.01); G01N 2333/775 (2013.01); G01N 2440/38 (2013.01); G01N 2800/26 (2013.01); G01N 2800/52 (2013.01)]

2 Claims

1. A method for treating corona 19 infection (COVID-19) in a subject in need thereof, said method comprising administering non-glycated HDL (high-density lipoprotein) to the subject, wherein the non-glycated HDL has killing activity against coronavirus (SARS-Co-V-2), and wherein the non-glycated HDL is isolated from human serum and has a diameter of 18 to 21 nm.